Gastrointestinal diseases are quite common all over the globe, and various treatments are available to tackle these health issues. One such way is the proper administration of a variety of drugs, thereby constituting a distinct gastrointestinal drugs market from a global perspective.
This market is mainly being driven due to rapidly progressing interests in research activities happening in drug development-based activities all over the globe. Moreover, cases of such ailments are quite common in old-aged people, and a rising geriatric population is also increasing the demand of such drugs. In addition, changing lifestyles, unhealthy eating habits, and increasing levels of stress also are key factors driving growth in the global gastrointestinal drugs market. With innovative advancements occurring in the techniques implemented for curing such issues at a steady pace, the global gastrointestinal drugs market is anticipated to register splendid revenue in the years to come.
As per expert analysts, the global gastrointestinal drugs market is foretold to clock revenue valuation of US$61.6 bn by 2024, which is a decent increase from an initial valuation of US$45.5 bn clocked in 2015. This growth is prophesized to occur at a healthy CAGR of 4.90% during the forecast period from 2016 to 2024.
Acid Neutralizers Come Out as Winning Segment in the Market
The global gastrointestinal drugs market is segregated into various segments on the basis of various criteria such as drug class, route of administration, disorder type, distribution channel, and regional spread. Under drug class, acid neutralizers, anti-diarrheal and laxatives, antiemetic and anti-nauseants, anti-inflammatory drugs, biologics, and antispasmodic, are key segments. Acid neutralizers are further subdivided into antacids, h2 antagonists, and proton pump inhibitors, in the form of sub-segments. In terms of administration route, oral, parenteral and rectal make up for the gastrointestinal drugs market. Under disorder type, gastro-esophageal reflux disease, inflammatory bowel disease, and irritable bowel syndrome, are prime illness types that require the administration of drugs. Whereas, the drugs are sold through three key distribution channels: hospital pharmacies, retail pharmacies, and online pharmacies.
Among all the drug classes, a rising demand for prevention of gastroesophageal reflux disease (GERD) has led to an increasing use of acid neutralizers. In this way, the acid neutralizers segment holds a dominant position in the global gastrointestinal drugs market. Moreover, the cost efficiency of such neutralizers too has contributed towards the segment’s splendid growth and presence in the market. Even in future, compared to other segments present under the drug class criteria, acid neutralizers are expected to continue gaining extensive revenue for the global gastrointestinal drugs market.
Region-wise, the global gastrointestinal drugs market is spread across North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa. Of these, North America occupies the primary slot in terms of revenue generation in the market. This is mainly due to the presence of favorable reimbursement policies in this region, which are highly beneficial for the welfare of those affected by gastrointestinal issues. Moreover, rapidly increasing instances of various chronic diseases, wherein gastrointestinal problems might exist as a key symptom, also is a prime factor responsible for the market’s progress in North America. To be specific, the region had registered a share of more than 41% in 2016, compared to other regions. With a surge in the number of old-aged people present in North America, the sales of gastrointestinal drugs are prophesized to rapidly increase in the near future.
In terms of the vendor landscape, Abbott Laboratories, Allergan Plc, AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Janssen Biotech Inc., Sanofi, Takeda Pharmaceutical, and Valeant Pharmaceuticals Inc. are chief players operating in the global gastrointestinal drugs market.
Augmented Research and Development Activities to Boost Gastrointestinal Drugs Market
Gastrointestinal disorders are quite prevalent all over the world and there are a variety of medications and treatment methods available to address these health problems. One such method is proper drug administration, which has resulted in the development of a distinct gastrointestinal drugs industry on a global scale. This factor is likely to favour development of the global gastrointestinal drugs market in the years to come.
This demand is primarily motivated by the increasingly growing interest in drug development-related research activities taking place all over the world. Furthermore, such diseases are very prevalent in the elderly, and the need for such medicines is growing as the geriatric population grows. In addition, evolving diets, unhealthy dietary patterns, and the stress levels are all contributing to the expansion of the global gastrointestinal drugs market. With constant developments in the procedures used to treat such problems, the global gastrointestinal drugs market is expected to grow significantly in the coming years.
High Prevalence of GI Problems in the Geriatric Population to Spur Market Growth
The rising prevalence of gastrointestinal diseases around the world is a major factor in the gastrointestinal drugs market's growth. On the other hand, heavy funding, especially in scientific research for the expansion and advancement of these medicines, as well as increasing awareness about the efficacy of the therapies as well as the healing process, are significantly contributing to the growth of the market. In addition, technical advancements in the treatment process are expected to propel this market forward significantly in the coming years. The demand for these drugs is expected to rise due to an increase in the number of patients struggling with GI disorders as a result of dietary changes.
North America is expected to become the world's most active geographic market for gastrointestinal medicines. It is expected to gain a sizable chunk of the gastrointestinal drugs market in the coming years as a result of customer-friendly payment programmes for the treatment of chronic syndromes or diseases. Because of the increasing number of elderly people who are vulnerable to gastrointestinal diseases, North America is expected to maintain its dominance in the gastrointestinal drugs market.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gastrointestinal Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Gastrointestinal Drugs Market Overview
5. Market Dynamics
5.1. Drivers
5.1.1. Restraints
5.1.2. Opportunity
5.1.3. Trends
5.2. Porter’s Five Force Analysis
5.3. FDA Approved Biologics Products
5.4. Overview of Clinical Trials
5.5. Epidemiology of Gastrointestinal Disease: Global Scenario
5.6. Global prevalence of Inflammatory Bowel Disease in 2015
6. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Size (US$ Mn) Forecast By Drug Class
6.4.1. Acid Neutralizers
6.4.1.1. Antacids
6.4.1.2. H2 antagonists
6.4.1.3. Proton pump inhibitors
6.4.1.4. Helicobacter pylori eradication
6.4.2. Antidiarrheal and Laxatives
6.4.3. Antiemetic and Antinauseants
6.4.4. Anti-inflammatory drugs
6.4.5. Biologics
6.4.6. Others (Antispasmodic etc.)
6.5. Market Attractiveness By Drug Class
7. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends
7.4. Market Size (US$ Mn) Forecast By Route of Administration
7.4.1. Oral
7.4.2. Intravenous
7.4.3. Rectal
7.5. Market Attractiveness By Route of Administration
8. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Disorder Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Key Trends
8.4. Market Size (US$ Mn) Forecast By Disorder Type
8.4.1. Gastroesophageal Reflux Disease
8.4.2. Inflammatory Bowel Disease
8.4.3. Irritable Bowel Syndrome
8.5. Market Attractiveness By Disorder Type
9. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Key Trends
9.4. Market Size (US$ Mn) Forecast By Distribution Channel
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Market Attractiveness By Distribution Channel
10. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Policies and Regulations
10.3. Market Size (US$ Mn) Forecast By Region
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. Asia Pacific
10.3.5. Middle East and Africa
10.4. Market Attractiveness By Country/Region
11. North America Gastrointestinal Drugs Market Analysis and Forecast
11.1. Key Findings
11.2. Policies and Regulations
11.3. Key Trends
11.4. Market Value Forecast By Country
11.4.1. US
11.4.2. Canada
11.5. Market Size (US$ Mn) Forecast By Drug Class
11.5.1. Acid Neutralizers
11.5.1.1. Antacids
11.5.1.2. H2 antagonists
11.5.1.3. Proton pump inhibitors
11.5.1.4. Helicobacter pylori eradication
11.5.2. Antidiarrheal and Laxatives
11.5.3. Antiemetic and Antinauseants
11.5.4. Anti-inflammatory drugs
11.5.5. Biologics
11.5.6. Others (Antispasmodic etc.)
11.6. Market Size (US$ Mn) Forecast By Route of Administration
11.6.1. Oral
11.6.2. Intravenous
11.6.3. Rectal
11.7. Market Size (US$ Mn) Forecast By Disorder Type
11.7.1. Gastroesophageal Reflux Disease
11.7.2. Inflammatory Bowel Disease
11.7.3. Irritable Bowel Syndrome
11.8. Market Size (US$ Mn) Forecast By Distribution Channel
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Online Pharmacies
11.9. Market Attractiveness Analysis
11.9.1. By Country
11.9.2. By Drug Class
11.9.3. By Route of Administration
11.9.4. By Disorder Type
11.9.5. By Distribution Channel
12. Europe Gastrointestinal Drugs Market Analysis and Forecast
12.1. Key Findings
12.2. Policies and Regulations
12.3. Key Trends
12.4. Market Value Forecast By Country
12.4.1. Germany
12.4.2. France
12.4.3. U.K.
12.4.4. Italy
12.4.5. Russia
12.4.6. Spain
12.4.7. Rest of Europe
12.5. Market Size (US$ Mn) Forecast By Drug Class
12.5.1. Acid Neutralizers
12.5.1.1. Antacids
12.5.1.2. H2 antagonists
12.5.1.3. Proton pump inhibitors
12.5.1.4. Helicobacter pylori eradication
12.5.2. Antidiarrheal and Laxatives
12.5.3. Antiemetic and Antinauseants
12.5.4. Anti-inflammatory drugs
12.5.5. Biologics
12.5.6. Others (Antispasmodic etc.)
12.6. Market Size (US$ Mn) Forecast By Route of Administration
12.6.1. Oral
12.6.2. Intravenous
12.6.3. Rectal
12.7. Market Size (US$ Mn) Forecast By Disorder Type
12.7.1. Gastroesophageal Reflux Disease
12.7.2. Inflammatory Bowel Disease
12.7.3. Irritable Bowel Syndrome
12.8. Market Size (US$ Mn) Forecast By Distribution Channel
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.9. Market Attractiveness Analysis
12.9.1. By Country
12.9.2. By Drug Class
12.9.3. By Route of Administration
12.9.4. By Disorder Type
12.9.5. By Distribution Channel
13. Asia Pacific Gastrointestinal Drugs Market Analysis and Forecast
13.1. Key Findings
13.2. Policies and Regulations
13.3. Key Trends
13.4. Market Value Forecast By Country
13.4.1. China
13.4.2. Japan
13.4.3. India
13.4.4. Australia & New Zealand
13.4.5. India
13.4.6. Rest of Asia Pacific
13.5. Market Size (US$ Mn) Forecast By Drug Class
13.5.1. Acid Neutralizers
13.5.1.1. Antacids
13.5.1.2. H2 antagonists
13.5.1.3. Proton pump inhibitors
13.5.1.4. Helicobacter pylori eradication
13.5.2. Antidiarrheal and Laxatives
13.5.3. Antiemetic and Antinauseants
13.5.4. Anti-inflammatory drugs
13.5.5. Biologics
13.5.6. Others (Antispasmodic etc.)
13.6. Market Size (US$ Mn) Forecast By Route of Administration
13.6.1. Oral
13.6.2. Intravenous
13.6.3. Rectal
13.7. Market Size (US$ Mn) Forecast By Disorder Type
13.7.1. Gastroesophageal Reflux Disease
13.7.2. Inflammatory Bowel Disease
13.7.3. Irritable Bowel Syndrome
13.8. Market Size (US$ Mn) Forecast By Distribution Channel
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Market Attractiveness Analysis
13.9.1. By Country
13.9.2. By Drug Class
13.9.3. By Route of Administration
13.9.4. By Disorder Type
13.9.5. By Distribution Channel
14. Latin America Gastrointestinal Drugs Market Analysis and Forecast
14.1. Key Findings
14.2. Policies and Regulations
14.3. Key Trends
14.4. Market Value Forecast By Country
14.4.1. Brazil
14.4.2. Mexico
14.4.3. Rest of Latin America
14.5. Market Size (US$ Mn) Forecast By Drug Class
14.5.1. Acid Neutralizers
14.5.1.1. Antacids
14.5.1.2. H2 antagonists
14.5.1.3. Proton pump inhibitors
14.5.1.4. Helicobacter pylori eradication
14.5.2. Antidiarrheal and Laxatives
14.5.3. Antiemetic and Antinauseants
14.5.4. Anti-inflammatory drugs
14.5.5. Biologics
14.5.6. Others (Antispasmodic etc.)
14.6. Market Size (US$ Mn) Forecast By Route of Administration
14.6.1. Oral
14.6.2. Intravenous
14.6.3. Rectal
14.7. Market Size (US$ Mn) Forecast By Disorder Type
14.7.1. Gastroesophageal Reflux Disease
14.7.2. Inflammatory Bowel Disease
14.7.3. Irritable Bowel Syndrome
14.8. Market Size (US$ Mn) Forecast By Distribution Channel
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Market Attractiveness Analysis
14.9.1. By Country
14.9.2. By Drug Class
14.9.3. By Route of Administration
14.9.4. By Disorder Type
14.9.5. By Distribution Channel
15. Middle East & Africa Gastrointestinal Drugs Market Analysis and Forecast
15.1. Key Findings
15.2. Policies and Regulations
15.3. Key Trends
15.4. Market Value Forecast By Country
15.4.1. GCC countries
15.4.2. South Africa
15.4.3. Rest of Middle East & Africa
15.5. Market Size (US$ Mn) Forecast By Drug Class
15.5.1. Acid Neutralizers
15.5.1.1. Antacids
15.5.1.2. H2 antagonists
15.5.1.3. Proton pump inhibitors
15.5.1.4. Helicobacter pylori eradication
15.5.2. Antidiarrheal and Laxatives
15.5.3. Antiemetic and Antinauseants
15.5.4. Anti-inflammatory drugs
15.5.5. Biologics
15.5.6. Others (Antispasmodic etc.)
15.6. Market Size (US$ Mn) Forecast By Route of Administration
15.6.1. Oral
15.6.2. Intravenous
15.6.3. Rectal
15.7. Market Size (US$ Mn) Forecast By Disorder Type
15.7.1. Gastroesophageal Reflux Disease
15.7.2. Inflammatory Bowel Disease
15.7.3. Irritable Bowel Syndrome
15.8. Market Size (US$ Mn) Forecast By Distribution Channel
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies
15.9. Market Attractiveness Analysis
15.9.1. By Country
15.9.2. By Drug Class
15.9.3. By Route of Administration
15.9.4. By Disorder Type
15.9.5. By Distribution Channel
16. Competition Landscape
16.1. Market Player
16.2. Company Share Analysis (2016)
16.3. Company Profiles
16.3.1. Abbott Laboratories
16.3.1.1. Overview
16.3.1.2. Financials
16.3.1.3. Recent Developments
16.3.1.4. Strategy
16.3.2. Allergan Plc
16.3.2.1. Overview
16.3.2.2. Financials
16.3.2.3. Recent Developments
16.3.2.4. Strategy
16.3.3. AstraZeneca
16.3.3.1. Overview
16.3.3.2. Financials
16.3.3.3. Recent Developments
16.3.3.4. Strategy
16.3.4. Bayer AG
16.3.4.1. Overview
16.3.4.2. Financials
16.3.4.3. Recent Developments
16.3.4.4. Strategy
16.3.5. Boehringer Ingelheim GmbH
16.3.5.1. Overview
16.3.5.2. Financials
16.3.5.3. Recent Developments
16.3.5.4. Strategy
16.3.6. GlaxoSmithKline plc
16.3.6.1. Overview
16.3.6.2. Financials
16.3.6.3. Recent Developments
16.3.6.4. Strategy
16.3.7. Janssen Biotech, Inc.
16.3.7.1. Overview
16.3.7.2. Financials
16.3.7.3. Recent Developments
16.3.7.4. Strategy
16.3.8. Sanofi
16.3.8.1. Overview
16.3.8.2. Financials
16.3.8.3. Recent Developments
16.3.8.4. Strategy
16.3.9. Takeda Pharmaceutical
16.3.9.1. Overview
16.3.9.2. Financials
16.3.9.3. Recent Developments
16.3.9.4. Strategy
16.3.10. Valeant Pharmaceuticals, Inc.
16.3.10.1. Overview
16.3.10.2. Financials
16.3.10.3. Recent Developments
16.3.10.4. Strategy
List of Tables
Table 01: Biologics Products, Manufacturers & Trade Names
Table 02: Biologics Products, Manufacturers & Trade Names
Table 03: Overview of major clinical trials for Inflammatory Bowel Disease
Table 04: Overview of major clinical trials for Inflammatory Bowel Disease
Table 05: Overview of major clinical trials for Inflammatory Bowel Disease
Table 06: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 07: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizer (Drug Class), 2014–2024
Table 08: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 09: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 10: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 11: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 12: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 13: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 14: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class), 2014–2024
Table 15: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 16: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 17: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 18: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 19: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 20: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class), 2014–2024
Table 21: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 22: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 23: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 24: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 25: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 26: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class),
Table 27: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 28: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 29: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 30: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 31: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 32: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class), 2014-2024
Table 33: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 34: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 35: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 36: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 37: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 38: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers, 2014–2024
Table 39: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 40: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 41: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
List of Figures
Figure 01: Market Value Share, by Drug Class (2015)
Figure 02: Market Value Share, by Route of Administration (2015)
Figure 03: Market Value Share, by Disorder Type (2015)
Figure 04: Market Value Share, by Distribution Channel (2015)
Figure 05: Market Value Share, by Region (2015)
Figure 06: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 07: Global Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 08: Global Acid Neutralizers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 09: Global Antidiarrheal and Laxatives Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 10: Global Antiemetic and Antinauseants Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 11: Global Anti-inflammatory drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 12: Global Biologics Market Revenue (US$ Mn) and
Figure 13: Global Others (Antispasmodic etc.)Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 14: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class
Figure 15: Global Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 16: Global Oral Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 17: Global Parenteral Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 18: Global Rectal Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 19: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 20: Global Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 21: Global Gastroesophageal Reflux Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 22: Global Inflammatory Bowel Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 23: Global Irritable Bowel Syndrome Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 24: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Disorder Type, 2016–2024
Figure 25: Global Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 26: Global Hospital Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 27: Global Retail Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 28: Global Online Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 29: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Distribution Channel, 2016–2024
Figure 30: Global Gastrointestinal Drugs Market Value Share Analysis, by Region, 2016 and 2024
Figure 31: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Region
Figure 32: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
Figure 33: North America Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2016–2024
Figure 34: North America Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
Figure 35: North America Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 36: North America Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 37: North America Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 38: North America Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 39: North America Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
Figure 40: North America Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 41: North America Gastrointestinal Drugs Market Attractiveness Analysis, by Disorder Type, 2016–2024
Figure 42: North America Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
Figure 43: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
Figure 44: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2015
Figure 45: Europe Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
Figure 46: Europe Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 47: Europe Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 48: Europe Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 49: Europe Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 50: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
Figure 51: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 52: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 2016–2024
Figure 53: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
Figure 54: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
Figure 55: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2016–2024
Figure 56: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
Figure 57: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 58: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 59: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 60: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 61: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
Figure 62: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 63: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 2016–2024
Figure 64: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
Figure 66: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2016–2024
Figure 67: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
Figure 68: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 69: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 70: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 71: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 72: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
Figure 73: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 74: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 2016–2024
Figure 75: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
Figure 76: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
Figure 77: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2016–2024
Figure 78: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
Figure 79: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 80: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 81: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 82: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 83: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
Figure 84: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 85: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 2016–2024
Figure 86: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
Figure 87: Global Gastrointestinal Drugs Market Share Analysis, by Company, 2016 (Estimated)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Gastrointestinal Drugs Market
